AtaiBeckley acquired by Eli Lilly and Company
Eli Lilly and Company acquired AtaiBeckley, a drug development brand, on Sep 11, 2026.
Transaction summary
- Target
- AtaiBeckley
- Acquirer
- Eli Lilly and Company
- Seller
- -
- Announced
- -
- Completed
- 2026-09-11
- Geography
- -
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-10-08
- Latest update
- 2026-11-03
Value and multiples
100% enterprise value
USD 2.8B
100% enterprise value | USD
Basis: Estimated
Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.
EV / revenue
-
Period not stated
Basis: FundComb estimate
EV / EBITDA
-
EBITDA basis not stated
Basis: FundComb estimate
Basis
- Estimated enterprise value: USD 2.8bn.
Source summary
Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
ConfirmedAcquisition of AtaiBeckley by Eli Lilly and Company.
Open sourceContinue your research
Related transaction comps
Same buyer / investor
4E Therapeutics acquired by Eli Lilly and Company
2026-06-16 · Confirmed
View transaction → Same buyer / investorKelonia Therapeutics acquired by Eli Lilly and Company
2026-04-20 · Confirmed
View transaction → Same buyer / investorCrossBridge Bio acquired by Eli Lilly
2026-04-14 · Confirmed
View transaction → Same buyer / investorDermira acquired by Eli Lilly
2020-01-10 · Confirmed
View transaction →